http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#Head http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#assertion http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#provenance http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#pubinfo http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#assertion http://purl.obolibrary.org/obo/DOID_1067 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1067 http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00484 http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association http://www.w3.org/2000/01/rdf-schema#label brimonidine tartrate ophthalmic solution 2 is indicated for lowering intraocular pressure iop in patients with open angle glaucoma or ocular hypertension the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients this loss of effect appears with a variable time of onset in each patient and should be closely monitored brimonidine tartrate ophthalmic solution 2 is an alpha adrenergic agonist indicated for lowering intraocular pressure iop in patients with open angle glaucoma or ocular hypertension 1 http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00484 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#provenance http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#pubinfo http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig http://purl.org/nanopub/x/hasSignature EqYUYVwpVNOxvbwCXyqfXwbx5yEghlnNGvJTws+02x6ovYy+bgnWRp3myIc/nExV6gpAr4RVQAc0HwbdnNAICYU/wpr5WcymiMX/dNnGD7QygRs3EPUjXMfA1eKHoaW7gPGkCrsYRQ7kveQMrY5NuYNbdEXJPuK2Uow/1LtDaaI= http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://purl.org/dc/terms/created 2021-06-13T12:21:17.724+02:00 http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs